{
    "nctId": "NCT01990352",
    "briefTitle": "Correlate BRCA1 Protein Expression With Response to DNA Damaging Chemotherapy",
    "officialTitle": "A Single Arm Phase II Trial to Assess Association of BRCA1 Protein Expression With Overall Response Rate in Patients With Metastatic Breast Cancer on Pegylated Liposomal Doxorubicin",
    "overallStatus": "TERMINATED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 24,
    "primaryOutcomeMeasure": "Overall Response Rate for Metastatic Breast Cancer Patients With Low BRCA1 Protein Expression in Their Tumor, Treated With Pegylated Liposomal Doxorubicin",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Metastatic breast cancer and have formalin-fixed, paraffin embedded primary tumor available for testing BRCA1 protein expression\n* Adults over 18 years of age\n* Have resolution of all acute toxic effects of any prior chemotherapy or radiotherapy to NCI CTC grade \u2264 1 prior to study registration.\n* Be informed of the investigational nature of this study and provide written informed consent in accordance with institutional and federal guidelines prior to study specific screening procedures\n* Be willing and able to comply with the treatment plan, scheduled clinic visits, laboratory and oncological tests and other study procedures\n* Have a ECOG performance status of 0 - 2\n* Measurable disease by CT by RECIST 1.1 to evaluate response\n* Adequate bone marrow function defined as platelets 100 X 109 cells/L, neutrophils 1.5 x 109 cells/L, white blood cells (WBC) 3.0 x 109 cells/L and a hemoglobin 90 gm/L\n* Creatinine \\< 1.5 mg/dl or creatinine clearance \\> 40 ml/min\n* Liver function tests (AST and or ALT) should be 2 x upper limit of normal (ULN, defined as per laboratory where blood testing is done), total bilirubin 1.5 x ULN (except for patients with liver metastases, ALT and/or ALT 5 times the upper limit of normal is accepted)\n\nExclusion Criteria:\n\n* Myocardial infarction within 6 months of registration\n* Brain metastases unless documented to be controlled post completion of local therapy (surgery and/or radiation therapy) for at least four weeks prior to registration\n* Pregnant or breast feeding women. Women with child bearing potential must use effective measures to prevent pregnancy while receiving pegylated liposomal doxorubicin\n* Have a concurrent active non-breast malignancy except for non-melanoma skin cancer\n* Her2 positive tumors as defined by FDA guidelines(3+ immunohistochemical staining, defined as uniform, intense membrane staining of more than 10% of invasive tumor cells, and for cases with 2+ staining showing gene amplification by FISH, expressed as a ratio of more than 2 when comparing HER-2 gene and chromosome 17 fluorescent signals)",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}